Details

Autor(en) / Beteiligte

• Diebold, Martin
• Meola, Marco
• Purushothaman, Srinithi
• Siewert, Lena K
• Pössnecker, Elisabeth
• Roloff, Tim
• Lindberg, Raija Lp
• Kuhle, Jens
• Kappos, Ludwig
• Derfuss, Tobias
• Egli, Adrian
• Pröbstel, Anne-Katrin

Titel

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis

Ist Teil von

• Gut microbes, 2022, Vol.14 (1), p.2147055

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Mounting evidence points towards a pivotal role of gut microbiota in multiple sclerosis (MS) pathophysiology. Yet, whether disease-modifying treatments alter microbiota composition and whether microbiota shape treatment response and side-effects remain unclear. In this prospective observational pilot study, we assessed the effect of dimethyl fumarate (DMF) on gut microbiota and on host/microbial metabolomics in a cohort of 20 MS patients. Combining state-of-the-art microbial sequencing, metabolome mass spectrometry, and computational analysis, we identified longitudinal changes in gut microbiota composition under DMF-treatment and an increase in citric acid cycle metabolites. Notably, DMF-induced lymphopenia, a clinically relevant safety concern, was correlated with distinct baseline microbiome signatures in MS patients. We identified gastrointestinal microbiota as a key therapeutic target for metabolic properties of DMF. By characterizing gut microbial composition as a candidate risk factor for DMF-induced lymphopenia, we provide novel insights into the role of microbiota in mediating clinical side-effects.